Orasis Pharmaceuticals
Israel - HerzliyaPharmaceutical
Focus: Orasis Pharmaceuticals is an Israeli specialty pharma focused on eye-drop treatments, particularly pilocarpine-based formulations for presbyopia and other ophthalmic indications. The company operates as a small-to-mid-cap player with a concentrated revenue base.
Profile data last refreshed 21h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Orasis Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Orasis Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Orasis Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$43K Part DDeclining
LOE Approaching
Core revenue driver (100% of company revenue) but approaching loss of exclusivity, creating urgent pressure on pipeline transition.
Help build intelligence for Orasis Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.